Faculty profile

Christopher Pease

ResearcherUniversity of Ottawa

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Ottawa directory, so their courses and email address may be missing. Find their university profile.

Christopher Pease

Researcher

Health Sciences

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
3 publications in the last five years, latest in 2023.
Principal investigator on 1 research grant (1 CIHR), most recently in 2021.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Epidemiology Inuit Machine Learning Population Health Tuberculosis

Latest papers

Fever of Unknown Origin Secondary to Pulmonary Histoplasmosis in Scleroderma-Related Interstitial Lung Disease.
The American journal of medicine · 2023
Comparing the Hospital Frailty Risk Score and the Clinical Frailty Scale Among Older Adults With Chronic Obstructive Pulmonary Disease Exacerbation.
JAMA network open · 2023
Effect of implementation of a 12-dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: Interrupted time series design.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022

All 11 publications

Latest funding

The Taima TB wastewater study
CIHR · 2023 · Co-investigator
$3,037,050
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
CIHR · 2023 · Co-investigator
$1,154,425
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
CIHR · 2023 · Co-investigator
$4,617,694

All 6 grants and awards

11 publications.

Fever of Unknown Origin Secondary to Pulmonary Histoplasmosis in Scleroderma-Related Interstitial Lung Disease.

Stanton A, Mulpuru S, Pease C, Deslandes V, Souza C, Pakhale S

The American journal of medicine2023

DOI: 10.1016/j.amjmed.2022.11.018 PMID: 36502956

Comparing the Hospital Frailty Risk Score and the Clinical Frailty Scale Among Older Adults With Chronic Obstructive Pulmonary Disease Exacerbation.

Chin M, Kendzerska T, Inoue J, Aw M, Mardiros L, Pease C, Andrew MK, Pakhale S, Forster AJ, Mulpuru S

JAMA network open2023

DOI: 10.1001/jamanetworkopen.2022.53692 PMID: 36729458

Effect of implementation of a 12-dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: Interrupted time series design.

Alvarez GG, Sullivan K, Pease C, Van Dyk D, Mallick R, Taljaard M, Grimshaw JM, Amaratunga K, Allen C, Brethour K, Mulpuru S, Pakhale S, Aaron SD, Cameron DW, Alsdurf H, Hui C, Zwerling AA

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

DOI: 10.1016/j.ijid.2022.01.063 PMID: 35121126

Molecular Epidemiology of Mycobacterium tuberculosis To Describe the Transmission Dynamics Among Inuit Residing in Iqaluit Nunavut Using Whole-Genome Sequencing.

Alvarez GG, Zwerling AA, Duncan C, Pease C, Van Dyk D, Behr MA, Lee RS, Mulpuru S, Pakhale S, Cameron DW, Aaron SD, Patterson M, Allen J, Sullivan K, Jolly A, Sharma MK, Jamieson FB

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

DOI: 10.1093/cid/ciaa420 PMID: 32293676

Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.

Pease C, Alvarez G, Mallick R, Patterson M, Finn S, Habis Y, Schwartzman K, Kilabuk E, Mulpuru S, Zwerling A

BMJ open2021First author

DOI: 10.1136/bmjopen-2020-047514 PMID: 33986067

The latent tuberculosis infection cascade of care in Iqaluit, Nunavut, 2012-2016.

Pease C, Zwerling A, Mallick R, Patterson M, Demaio P, Finn S, Allen J, Van Dyk D, Alvarez GG

BMC infectious diseases2019First author

DOI: 10.1186/s12879-019-4557-3 PMID: 31651260

Social determinants of health among residential areas with a high tuberculosis incidence in a remote Inuit community.

Kilabuk E, Momoli F, Mallick R, Van Dyk D, Pease C, Zwerling A, Potvin SE, Alvarez GG

Journal of epidemiology and community health2019

DOI: 10.1136/jech-2018-211261 PMID: 30728201

Catheter Tract Metastasis in Mesothelioma Patients with Indwelling Pleural Catheters: A Retrospective Cohort Study.

Mitchell MA, Li P, Pease C, Hosseini S, Souza C, Zhang T, Amjadi K

Respiration; international review of thoracic diseases2019

DOI: 10.1159/000494500 PMID: 30544117

A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.

Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, Skidmore B, Alvarez GG

Pharmacoepidemiology and drug safety2018First author

DOI: 10.1002/pds.4423 PMID: 29573031

Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.

Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, Skidmore B, Moher D, Alvarez GG

BMC infectious diseases2017First author

DOI: 10.1186/s12879-017-2377-x PMID: 28399802

Something wrong or missing on this profile? Suggest a correction

Christopher Pease

Research

Latest papers

Latest funding

Fever of Unknown Origin Secondary to Pulmonary Histoplasmosis in Scleroderma-Related Interstitial Lung Disease.

Comparing the Hospital Frailty Risk Score and the Clinical Frailty Scale Among Older Adults With Chronic Obstructive Pulmonary Disease Exacerbation.

Effect of implementation of a 12-dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: Interrupted time series design.

Molecular Epidemiology of Mycobacterium tuberculosis To Describe the Transmission Dynamics Among Inuit Residing in Iqaluit Nunavut Using Whole-Genome Sequencing.

Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.

The latent tuberculosis infection cascade of care in Iqaluit, Nunavut, 2012-2016.

Social determinants of health among residential areas with a high tuberculosis incidence in a remote Inuit community.

Catheter Tract Metastasis in Mesothelioma Patients with Indwelling Pleural Catheters: A Retrospective Cohort Study.

A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.

Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.

The Taima TB wastewater study

Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)

Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)

Access to care and the economic burden of tuberculosis in Ontario during the COVID-19 pandemic: illuminating inequities to support public health policy

Focused community TB screening among high risk residential zones in Nunavut: The TAIMA TB household risk prediction study

Modelling the impact and cost-effectiveness of novel approaches for TB control in Nunavut

Frequent collaborators

Sunita Mulpuru

Smita Pakhale

Alice Zwerling

Brian Hutton

Charles Hui

Kayvan Amjadi

Paul Wheatley-Price

Gonzalo Alvarez

Franco Momoli

Tetyana Kendzerska

David Moher

Monica Taljaard

Kevin Schwartzman